The Technical Analyst
Syndax Pharmaceuticals [SNDX]
Exchange: Nasdaq Global Select Sector: Healthcare Industry: Biotechnology
Syndax Pharmaceuticals Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
-0.88% $19.07
Last updated: 3 jul 2022 - 20:17
TimeZone: America/New_York
FIND ALL MARKETS
FIND ALL STOCKS LISTED @ NASDAQ Live Signal Oslo
Live Signal Nasdaq
Live Signal Crypto
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 1 072.35 mill |
| EPS: | 0.370 |
| P/E: | 51.54 |
| Earnings Date: | Aug 08, 2022 |
| SharesOutstanding: | 56.23 mill |
| Avg Daily Volume: | 0.606 mill |
| RATING 2022-07-01 |
|---|
| B+ |
| Buy |
| RATINGDETAILS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Neutral | |
| Return On Asset: | Neutral | |
| DE: | Neutral | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/20 | 1/21 | 2/21 | 3/21 | 4/21 | 1/22 | |
| Revenue | n/a | n/a | n/a | |||
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | |
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.11x |
| Company: PE 51.54 | sector: PE 480.39 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| infx |
| Company: PE 51.54 | industry: PE 0.000 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$23.34 (22.40%) $4.27 |
| Date: 2022-07-04 |
| True Range Average |
|---|
|
+/- $0.963 ( +/- 5.05%) Range: 18.11 - 20.03 |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2022-06-13 | Goldan Keith A. | Buy | 230 000 | Stock Options (Right to buy) |
| 2022-06-13 | Goldan Keith A. | Buy | 3 205 | Common Stock |
| 2022-04-04 | Morrison Briggs | Sell | 3 128 | Stock Options (Right to buy) |
| 2022-04-04 | Morrison Briggs | Buy | 3 128 | Common Stock |
| 2022-04-04 | Morrison Briggs | Sell | 3 128 | Common Stock |
| INSIDER POWER |
|---|
| 40.91 |
| Last 100 transactions |
| Buy: 1 871 770 | Sell: 872 805 |
Forecast:
16:00 - $19.07
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $19.07
Forecast 2: 16:00 - $19.07
Forecast 3: 16:00 - $19.07
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $19.07 (-0.88% ) |
| Volume | 0.350 mill |
| Avg. Vol. | 0.606 mill |
| % of Avg. Vol | 57.81 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For SNDX
30 Signals | Accuracy: 6.67% | Accuracy Buy: 6.67% | Accuracy Sell: 6.67%
Avg return buy: -0.20 % | Avg return sell: 0.17 %
$1 invested is now $0.97 or -2.91% since 30-06-22
| Date | Signal | @ | Closed | % | Jul 1 - 15:14 | buy | $18.96 | N/A | Active |
|---|---|---|---|---|
| Jul 1 - 11:35 | sell | $19.22 | $18.96 @ Jul 1 - 15:14 | -1.35% |
| Jul 1 - 11:26 | buy | $19.32 | $19.22 @ Jul 1 - 11:35 | -0.52% |
| Jul 1 - 09:32 | sell | $19.17 | $19.32 @ Jul 1 - 11:26 | 0.78% |
| Jun 30 - 16:12 | buy | $19.24 | $19.17 @ Jul 1 - 09:32 | -0.36% |
| Jun 30 - 15:50 | sell | $19.24 | $19.24 @ Jun 30 - 16:12 | 0.00% |
| Jun 30 - 15:46 | buy | $19.26 | $19.24 @ Jun 30 - 15:50 | -0.10% |
| Jun 30 - 15:41 | sell | $19.24 | $19.26 @ Jun 30 - 15:46 | 0.10% |
| Jun 30 - 15:38 | buy | $19.28 | $19.24 @ Jun 30 - 15:41 | -0.21% |
| Jun 30 - 15:29 | sell | $19.24 | $19.28 @ Jun 30 - 15:38 | 0.21% |
SNDX
Latest Press Releases
2022-06-16 16:30:00 - Press Release
Syndax Pharmaceuticals Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Waltham, mass. , june 16, 2022 /prnewswire/ -- syndax pharmaceuticals, inc. ("syndax," the "company" or "we") (nasdaq: sndx), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that in connection with the hiring, announced on june 13, 2022, of keith a.
2022-06-13 07:30:00 - Press Release
Syndax Pharmaceuticals Announces Appointment Of Keith A. Goldan As Chief Financial Officer
Waltham, mass. , june 13, 2022 /prnewswire/ -- syndax pharmaceuticals, inc. ("syndax," the "company" or "we") (nasdaq: sndx), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the appointment of keith a.
2022-05-11 07:00:00 - Press Release
Syndax Announces Participation At Citi's Biopharma Virtual Co-panel Day
Waltham, mass. , may 11, 2022 /prnewswire/ -- syndax pharmaceuticals, inc. ("syndax," the "company" or "we") (nasdaq: sndx), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that michael a.
2022-01-20 07:00:00 - Press Release
Syndax Announces Presentation At B. Riley Securities' 2022 Oncology Conference
Waltham, mass., jan. 20, 2022 /prnewswire/ -- syndax pharmaceuticals, inc. ("syndax," the "company" or "we") (nasdaq: sndx), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of its management team will participate in a fireside chat at b.
2022-01-07 07:00:00 - Press Release
Syndax Announces Presentation At 40th Annual J.p. Morgan Healthcare Conference
Waltham, mass., jan. 7, 2022 /prnewswire/ -- syndax pharmaceuticals, inc. ("syndax," the "company" or "we") (nasdaq: sndx), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that briggs w.
Latest News
2022-05-26 07:00:00 - PRNewsWire
Syndax Announces Participation at Two Upcoming Investor Conferences
WALTHAM, Mass. , May 26, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of its management team will participate in two upcoming investor conferences: A virtual fireside chat at Cowen's 3rd Annual Oncology Innovation Summit at 12:30 p.m.
2022-04-10 07:30:36 - InvestorPlace
Do Penny Stocks Ever Make Money? Here Are 7 Success Stories
Penny stocks can make money. Success stories include Advanced Micro Devices, a former penny stock that earned a $3.2 billion net income in 2021.
2022-04-08 00:59:12 - Seeking Alpha
Syndax Pharmaceuticals: Cash-Rich With 2 Promising Drugs
Today's $19 share quote is backed by as much as $7.50 in cash vs. total liabilities under $1 per unit. Larger drug trials are underway testing the usefulness of two cancer-related products.
2022-03-01 22:37:09 - Seeking Alpha
Syndax Pharmaceuticals, Inc. (SNDX) CEO Michael Metzger on Q4 2021 Results - Earnings Call Transcript
Syndax Pharmaceuticals, Inc. (SNDX) CEO Michael Metzger on Q4 2021 Results - Earnings Call Transcript
2021-12-14 06:22:06 - Benzinga
Syndax Pharma Posts Additional Data On Clinical Activity, Responses From Early-Stage Leukemia Trial
Syndax Pharmaceuticals Inc (NASDAQ: SNDX) revealed updated data from the Phase 1 dose-escalation portion of the AUGMENT-101 trial of SNDX-5613 in patients with mutant nucleophosmin (mNPM1) or mixed-lineage leukemia rearranged (MLLr) relapsed/refractory acute leukemias. The data were featured at the American Society of Hematology (ASH) Annual Meeting.
2021-11-15 21:01:09 - Seeking Alpha
Syndax Pharmaceuticals, Inc. (SNDX) CEO Briggs Morrison on Q3 2021 Results - Earnings Call Transcript
Syndax Pharmaceuticals, Inc. (SNDX) CEO Briggs Morrison on Q3 2021 Results - Earnings Call Transcript
2021-11-04 09:24:00 - PRNewsWire
Syndax Pharmaceuticals to Present Updated Data from SNDX-5613 and Axatilimab Clinical Programs During Oral Sessions at 63rd ASH Annual Meeting
WALTHAM, Mass., Nov. 4, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that updated data from both of its ongoing SNDX-5613 and axatilimab programs will be featured during oral sessions at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition being held December 11-14, 2021.
2021-09-28 13:54:10 - Zacks Investment Research
Incyte (INCY) Collaborates With Syndax for Chronic GVHD Candidate
Incyte (INCY) collaborates with Syndax to develop and commercialize axatilimab for chronic graft-versus-host disease and other fibrotic diseases.
2021-09-27 09:23:11 - Benzinga
Syndax Pharma, Incyte Ink Licensing Pact For Graft Vs. Host Disease Candidate
Syndax Pharmaceuticals Inc (NASDAQ: SNDX) and Incyte Corporation (NASDAQ: INCY) have entered into an exclusive worldwide collaboration and license agreement to develop and commercialize Syndax's axatilimab. Related Content: Syndax Pharma Receives FDA Orphan Drug Designation For Axatilimab For Treatment Of Chronic Graft vs.
2021-09-27 08:10:55 - Pulse2
SNDX Stock: Why It Increased Today
The stock price of Syndax Pharmaceuticals Inc (NASDAQ: SNDX) increased by over 14% today. This is why it happened.